We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Aventis Faces Threat Of Generic Competition For Lovenox

Law360 (March 15, 2004, 12:00 AM EST) -- A U.S. biotechnology company headed for an initial public offering plans to produce a generic version of Aventis’ anti-blood clotting drug Lovenox.

Momenta Pharmaceuticals Inc., which filed with the Securities and...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.